Madrigal, Suzhou Ribo in license deal for liver‑disease programs

Madrigal Pharmaceuticals

11/02/2026 10:10

Feb 11 (Reuters) - Madrigal Pharmaceuticals MDGL.O said on Wednesday it has signed an exclusive global license agreement with China-based Suzhou Ribo Life Science 6938.HK and its subsidiary Ribocure Pharmaceuticals for six preclinical small interfering RNA programs to treat a type of liver disease.

 (Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber)

 ((siddhi.mahatole@thomsonreuters.com;))